Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the elicitation of a specific SARS-CoV-2 antibody response. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hueso, Thomas, Pouderoux, Cécile, Péré, Hélène, Beaumont, Anne-Lise, Raillon, Laure-Anne, Ader, Florence, Chatenoud, Lucienne, Eshagh, Déborah, Szwebel, Tali-Anne, Martinot, Martin, Camou, Fabrice, Crickx, Etienne, Michel, Marc, Mahevas, Matthieu, Boutboul, David, Azoulay, Elie, Joseph, Adrien, Hermine, Olivier, Rouzaud, Claire, Faguer, Stanislas, Petua, Philippe, Pommeret, Fanny, Clerc, Sébastien, Planquette, Benjamin, Merabet, Fatiha, London, Jonathan, Zeller, Valérie, Ghez, David, Veyer, David, Ouedrani, Amani, Gallian, Pierre, Pacanowski, Jérôme, Mékinian, Arsène, Garnier, Marc, Pirenne, France, Tiberghien, Pierre, Lacombe, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702482/
https://www.ncbi.nlm.nih.gov/pubmed/32959052
http://dx.doi.org/10.1182/blood.2020008423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702482/
https://www.ncbi.nlm.nih.gov/pubmed/32959052
http://dx.doi.org/10.1182/blood.2020008423

Ejemplares similares